Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ER-851 |
| Synonyms | |
| Therapy Description |
ER-851 selectively inhibits AXL, potentially leading to decreased cell viability and reduced of tumor growth (PMID: 36279567). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ER-851 | ER-001259851-000|ER851|ER 851 | AXL Inhibitor 30 | ER-851 selectively inhibits AXL, potentially leading to decreased cell viability and reduced of tumor growth (PMID: 36279567). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL positive | Advanced Solid Tumor | sensitive | ER-851 | Preclinical - Cell culture | Actionable | In a preclinical study, ER-851 decreased viability of transformed cells expressing AXL in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 36279567). | 36279567 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|